This report was first published by Endpoints News. To see the original version, click here
AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that’s become a go-to place for drug R&D and industry dealmaking in the past year.
The UK pharma giant said Thursday it will pump $15 billion into China through 2030 to bolster manufacturing of medicines and ramp up R&D in what has proven to be the most efficient region for early-stage drug development. This includes the $2.5 billion announced in March 2025 to expand vaccine manufacturing and open a research site in Beijing to complement its existing labs in Shanghai.
您已阅读20%（674字），剩余80%（2686字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。